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Abstract
Background Peritoneal carcinomatosis is an unmet med-
ical need. Laparoscopy offers a unique opportunity to
control and to steer the operating environment during
surgery by loading carbon dioxide with a therapeutic sub-
stance and creating the so-called therapeutic capnoperito-
neum. We have treated a human sample of peritoneal
carcinomatosis from an endometrial adenocarcinoma ex
vivo just after surgery.
Methods A nontoxic therapeutic agent (Dbait) was aero-
solized into a box containing diseased human peritoneum
under a pressure of 12 mmHg CO2. Dbait (noncoding DNA
fragments) acts through jamming DNA damage sensing
and signaling, ultimately inhibiting DNA repair system of
cancer cells. Dbait were coupled to cholesterol molecules
to facilitate intracellular uptake, and to Cyanine (Cy5) to
allow detection by ﬂuorescence. In a control experiment,
the same solution was applied to the other half of the
sample using conventional lavage.
Results Physical results revealed ﬂuorescence within the
tumor up to 1 mm depth in the therapeutic capnoperito-
neum sample and no uptake in the lavage sample. Bio-
logical results showed intranuclear phosphorylation of
H2AX in the nebulized sample and no activity in the lavage
sample. Importantly, tumor nodules showed more activity
than the neighbor, normal peritoneum. Detection of histone
gamma-H2AX (phosphorylated H2AX) reveals activation
of DNA-dependent protein kinase (DNA-PK) by Dbait,
which has been shown to be the key step for sensitization to
genotoxic therapy.
Conclusions Dbait are taken up by cancer cells and have
a biological activity up to 1 mm depth. Nebulization of the
molecule is signiﬁcantly more effective than conventional
lavage. This proof of principle supports the need for clin-
ical studies applying therapeutic capnoperitoneum together
with Dbait for treating peritoneal carcinomatosis.
Keywords Laparoscopic surgery  Peritoneum-therapy 
Nebulizer  Cancer  Pneumoperitoneum  Dbait
Peritoneal carcinomatosis (PC) is a devastating form of
cancer progression with a very poor prognosis. Chemother-
apyhasonlylimitedeffectduetodrugresistanceinadvanced
tumor stages and to poor bioavailability within the abdomi-
nal cavity after systemic drug application. Current therapy,
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and Other Interventional Techniques when possible, includes cytoreductive surgery associated or
not with hyperthermic intraperitoneal chemotherapy [1].
However, this therapy is linked to signiﬁcant morbidity and
mortality, and results are still limited [2]. Thus, there is a
need for novel therapeutic approaches, including preventive
strategies during initial surgery [3].
The ability of cancer cells to recognize damage and
initiate DNA repair is an important mechanism of resis-
tance to treatment. Pharmacological inhibition of DNA
repair for a short period during treatment has the potential
to make cancer cells more vulnerable to the damaging
effects of therapy, therefore increasing the response to
treatment [4]. Dbait acts by baiting and hijacking the
enzyme complexes that repair DNA double strand breaks
(DSB), diverting them away from their primary objective,
the DSBs on chromosomes [5]. Such DSB are currently
caused by treatment, such as radiotherapy (RT) and DNA-
damaging chemotherapy (CT). Dbait increases the sensi-
tivity of HNCC, melanoma and glioblastoma to irradiation
[6], and the sensitivity of colorectal cancer to chemother-
apy [7]. However, a limitation of this approach is tumor
access and penetration into tumor nodes, so that it can only
be applied to superﬁcially spreading tumors.
Laparoscopy offers a unique opportunity to control and
to steer the operating environment during surgery, by
loading carbon dioxide with a therapeutic substance and
creating the so-called therapeutic capnoperitoneum [8].
Recently, we have shown that therapeutic peritoneum
allows homogeneous distribution of a therapeutic substance
within the peritoneal cavity and an improved penetration
depth into normal and diseased tissue compared with
conventional peritoneal lavage [9].
However, working with toxic therapeutic aerosols is only
possible under strongly regulated conditions. Interestingly,
preclinical studies with Dbait in the primate have shown no
toxicity of the molecule on healthy tissues (data on ﬁle).
Thus, there is a rationale for combining Dbait with thera-
peutic capnoperitoneum to obtain a synergy. In particular,
local increase in chemosensitivity could improve efﬁcacy of
both intraperitoneal and systemic chemotherapy on PC.
The general purpose of the present ex vivo experiment
was to test possible advantages of combining both tech-
nologies for treating a human PC tumor nodule, in partic-
ular concerning tumor access (distribution and
penetration). A second speciﬁc goal was to examine whe-
ther genotoxicity can be demonstrated in a tumor nodule of
human PC after loading capnoperitoneum with Dbait.
Material and methods
The current study was designed to investigate the biodis-
tribution of Dbait in a PC nodule ex vivo, immediately
after surgical resection. For this purpose, a tumor nodule
was exposed to Dbait aerosol using the micropump
(MIP) spraying device under 12 mmHg of CO2 pressure
in a closed box modeling the peritoneal cavity. An
electrical gradient was generated to focus drug distri-
bution onto the peritoneal surface and to enhance tissue
penetration (Fig. 1). As controls, two further experi-
ments were conducted: (1) the experiment as above
without Dbait, and (2) lavage of a PC nodule with Dbait
in a glucose solution.
The following parameters have been measured:
(a) Surface homogeneity of Dbait distribution within the
simulated peritoneal cavity,
(b) Dbait diffusion into the peritoneal nodule, and
(c) Dbait’s bioactivity in cancer cells under oxidative
stress.
Study design
This ex vivo study involved tumor tissue from a single
human patient suffering PC from endometrial origin.
Because patient therapy was not inﬂuenced by the experi-
ment, no authorization from an ethical committee was
required. Ex vivo research on human tissue is allowed at
our institution by a valid authorization of the common
ethics committee of the Westfalian University—Medical
Chamber of Westfalia-Lippe (AeKWL).
Fig. 1 Laparoscopy-like ex vivo experiment on fresh operation
specimen of diseased human peritoneum (peritoneal carcinomatosis
from endometrial origin). Therapeutic capnoperitoneum (12 mmHg)
was established in a plastic box. An electrostatic gradient of 60 V was
generated between the MIP and the biological tissue, placed on a
neutral electrode. MIP micropump
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The nebulizer has been described elsewhere [9] and con-
sists of several components, including an injector, a line,
and a nozzle. The nozzle had a diameter of 0.2 mm, and a
pressure of approximately 8 bars was delivered upfront of
the nozzle. The nebulizer was inserted through a 10-mm
trocar and generated an aerosol within the plastic box
mimicking the abdominal cavity. The gaseous phase con-
sisted of CO2, the liquid phase of microparticles of Dbait
(100 lg/ml).
Patient characteristics, cytoreduction,
and intraperitoneal hyperthermic chemotherapy
A female patient suffering PC from endometrial cancer was
selected for the experiment and gave her written, informed
consent. Chloroquine 100 mg qd was administered for
1 week before the operation. First, a complete cytoreduc-
tion was achieved (CRS). In a second step, intraperitoneal
hyperthermic chemotherapy was applied with cisplatin
75 mg/m
2 body surface and doxorubicin 15 mg/m
2 body
surface, according to usual protocols.
Tumor characteristics
Immediately after surgical cytoreduction, a peritoneal
fragment of approximately 10 9 10 cm, showing macro-
scopic peritoneal nodules, was selected for experimental
purpose. The remaining surgical specimen was sent to the
pathologist for diagnostic purpose. Microscopic analysis
showed a poorly differentiated (G3) clear cell adenocarci-
noma with few small necrosis foci.
Experimental protocol
The three surgical samples were treated as follows:
a) The ﬁrst peritoneal nodule was inserted into the
experimental box, placed on the electrode, and
exposed to CO2 capnoperitoneum at room temperature
for 30 minutes. After dilution into 90 ml of glucose
5%, 9 mg of Cy5-labelled Dbait (1:1 dilution with non
ﬂuorescent Dbait) was aerosolized into the box.
b) A second peritoneal nodule was exposed to ‘‘perito-
neal lavage’’ using 0.1 mg/ml Dbait-Cy5 diluted into
10 ml of glucose 5%.
c) A third peritoneal nodule was exposed to identical
conditions as (a) without Dbait (negative control).
Immediately after the experiment, all three samples
were split into two halves: the ﬁrst half was ﬁxed in for-
malin solution and sent to the pathologist, the second half
was immediately frozen at -80C for further biological
analysis.
Microscopic analysis
For analysis, formalin-ﬁxed specimens were stained with
H&E according to usual protocols. For microscopic ﬂuo-
rescence analysis, sampled were ﬁxed with PFA 4% for
20 min at room temperature (RT), followed by exposure to
Triton 0.5% for 10 min at RT. Then, samples were washed
out in SVF diluted  in PBS solution for 1 h at RT, fol-
lowed by incubation with c-H2AX mouse antibody (Mil-
lipore, Billerica, MA, USA) diluted 1/200 (SVF  in PBS)
for 2 h at RT. After washing, samples were incubated with
secondary anti-mouse FITC (Sigma-Aldrich Chimie Sarl.,
Lyon, France) diluted 1/100 for 45 min at RT. Nuclei were
counterstained with Dapi 0.5 lg/ml for 5 min at room
temperature. Analysis was performed with an inverted
microscope.
Results
The experiment was performed according to the schedule.
No technical difﬁculty was encountered. In particular, MIP
generated the Dbait-aerosol without any difﬁculty. Remote
control of the injection device was possible without direct
intervention in the operating room. All six sides of the
experimental box were stained; however, an intensity
gradient was observed from the bottom to the top of the
box (not shown).
Microscopic analysis revealed homogeneous peritoneal
distribution of Dbait-Cy5 in the therapeutic capnoperito-
neum sample (arrows), only minimal uptake in the lavage
sample, and no staining (or only marginal staining) in the
control sample (Fig. 2). Fluorescence was detected within
the tumor up to 1 mm depth in the therapeutic capnoperi-
toneum sample but not in the lavage sample (Fig. 3). Thus,
aerosolization of the molecule allowed signiﬁcantly better
tumor access and better bioavailability of Dbait than con-
ventional lavage.
Biological results showed intranuclear phosphorylation
of H2AX in the nebulized sample and almost no activity in
the lavage sample (Fig. 4). The low activity detected in the
lavage sample is due to the presence of spontaneous
chromosomal damage in PC cells. Detection of histone
gamma-H2AX (phosphorylated H2AX) reveals the nuclear
activation of DNA-dependent protein kinase (DNA-PK) by
Dbait. Dbait was taken up by cancer cells, and a biological
activity was detected up to 1 mm depth. Importantly, tumor
nodules showed more activity at the tumor invasion front
(Fig. 5).
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This ex vivo experiment was designed to examine
possible advantages of combining Dbait with therapeutic
capnoperitoneum for treating a human tumor nodule of
PC ex vivo, in particular concerning tumor access
(distribution and penetration). A second speciﬁc goal
was to examine whether bioactivity of Dbait could be
demonstrated.
This is the ﬁrst time that biological activity of Dbait is
proved in human patient tissue. So far, experiments have
been performed in human tumor xenograft models in the
Fig. 2 Diffusion of therapeutic substance onto the peritoneum.
I. Cryosection of human peritoneum, red: Dbait-Cy5 staining, blue:
Dapi (nucleus). A After nebulization of Dbait, B after lavage with
Dbait, C after nebulization without Dbait. Staining reveals
homogeneous peritoneal ﬂuorescence in the therapeutic capnoperito-
neum sample (arrows), only minimal uptake in the lavage sample,
and no staining in the control sample. II: H&E staining
Fig. 3 Penetration of therapeutic substance into the peritoneum.
Cryosection of human peritoneum, red: Dbait-Cy5 staining, blue dapi
(nucleus). A After nebulization of Dbait, B after lavage with Dbait,
C after nebulization without Dbait. Staining reveals ﬂuorescence up
to seven cellular layers in the therapeutic capnoperitoneum sample
(A), no tissue uptake in the lavage sample (B) and no staining in the
control sample (C)
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approval of Dbait for therapeutic use in patients.
The above-mentioned results are encouraging, because
they evidence a homogeneous distribution of Dbait onto
peritoneum and a better penetration into peritoneum than
after conventional peritoneal lavage. This excellent bio-
availability of Dbait in human peritoneal tissue ex vivo
conﬁrms the results obtained previously in the large-animal
model showing a better vital staining of the abdominal cavity
afteraerosolizationthanafterlavagewithmethyleneblue[9].
Another important ﬁnding was intranuclear phosphory-
lation of H2AX in the nebulized sample, proving Dbait
uptake up to 1 mm depth, and showing biological activity.
Detection of histone gamma-H2AX (phosphorylated
H2AX) reveals nuclear activation of DNA-PK by Dbait, a
signiﬁcant result because this activation has been shown to
be the key step for sensibilization to genotoxic therapy
[5, 6]. Moreover, this result has been obtained under oxi-
dative stress conditions (warm ischemia) in human tumoral
tissue—and not in an animal model. Importantly, tumor
nodules showed more activity than the neighbor, normal
peritoneum, in particular at the tumor invasion front. Thus,
the present experiment delivers the proof of principle
for combining Dbait with systemic or intraperitoneal
Fig. 4 Biological activity. Cryosection of human peritoneum.
Detection of early Dbait activity marker: Phosphorylated H2AX.
Red: Dbait-Cy5 staining, blue: Dapi staining (nucleus), green:
c-H2AX. A After nebulization of Dbait, B after lavage with Dbait.
Intranuclear phosphorylation of H2AX is observed the nebulized
sample and only artifactual staining (no nuclear staining) in the lavage
sample. Detection of histone c-H2AX (phosphorylated H2AX)
reveals activation of DNA-Phosphokinase by Dbait, which has been
shown to be the key step for sensibilization to genotoxic therapy
Fig. 5 Tumor speciﬁcity. Detection of early Dbait activity marker: cryosection of human peritoneum; A blue: Dapi staining (nucleus); B green:
c-H2AX after nebulization of Dbait, C red: Dbait-Cy5 staining, D merged: H2AX activation is maximal at the tumor invasion front (arrow)
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this proof of principle ex vivo should now be conﬁrmed by
corresponding in vivo studies.
Current intraperitoneal hyperthermic chemotherapy
guidelines recommend the application of an intraperitoneal
temperature of 41–43C[ 10]. Recently, we observed that
numerous Heat Shock proteins were phosphorylated in cells
treated by Dbait. Moreover, in vitro, Dbait sensitize cells to
temperature shift (unpublished data). Thus, it will be
interesting to perform these efﬁcacy studies under hyper-
thermic conditions to increase the biological effect of Dbait.
In this experiment, biological response was observed
already after less than 1 h. This was a surprise because
preclinical data obtained in the animal model showed
maximal biological response after 3 h. This can be
explained by the application of an electrostatic gradient of
60 V, which is similar to the condition of cellular electro-
poration.Thiswasobviouslyhelpfulforuptakeofverylarge
amounts of Dbait molecules. Preoperative therapy with
chloroquine also might have contributed to this improved
cellular drug uptake: chloroquine is known to fragilize the
membranes of the endosomes, so that the release of Dbait
molecules into the cytoplasm is facilitated [11].
The biological effect was achieved with a low Dbait
dose, only 9 mg for a volume corresponding to the entire
abdominal cavity. Dbait effect is strictly dose-dependent,
as demonstrated in several tumor systems [6]. In the pre-
clinical model, a dose of 4 mg was considered adequate for
treating small tumor xenografts (data submitted). Thus, an
excellent intracellular uptake of Dbait was achieved under
experimental conditions.
Another, major point of interest is that Dbait has shown
no toxicity in preclinical studies in the primate (data on
ﬁle). Thus, aerosolization of Dbait might be possible in
clinical practice without particular safety measures for
protecting both patient and surgical team. This favorable
safety proﬁle might speed up implementation of thera-
peutic capnoperitoneum in cancer surgery.
In summary, combining Dbait with therapeutic capno-
peritoneum appears to have several practical advantages.
Peritoneal carcinomatosis is a superﬁcial and diffuse tumor
that is accessible to Dbait. Pressure enhances Dbait pene-
tration into tumor tissue. CO2 as a carrier ensures excellent
drug distribution onto the peritoneum. Application of an
electrostatic gradient optimizes both drug distribution and
drug uptake, probably by inducing cellular electroporation.
Dbait has no toxicity demonstrated in the primate so that its
clinical use appears easily possible. Finally, intraperitoneal
hyperthermia might enhance the efﬁcacy of Dbait by cre-
ating cellular stress, but this has not been investigated in
the present proof-of-principle experiment.
The development of procedures easily applicable to the
clinical setting that might improve outcome in PC should be
givenhighpriority.Thisproof-of-principle experimentopens
a new avenue for treating PC that should now be followed by
adequate clinical studies, a precondition for regulatory
approval of this new, challenging therapeutic approach.
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